Anthropic has made its first acquisition, and the numbers are startling. The AI company paid approximately $400 million in stock for Coefficient Bio, a stealth biotech startup with fewer than 10 employees, no revenue, and roughly eight months of existence. [1]

The team — nearly all former Genentech computational biology researchers — will join Anthropic's healthcare and life sciences group, which develops AI tools for drug discovery and molecular analysis. [2] The deal was all-stock, meaning Anthropic's equity valuation absorbs the cost without cash burn. At Anthropic's current private valuation, $400 million is a rounding error on paper.

What it signals is more important than what it costs. Anthropic is betting that frontier AI models — Claude and its successors — can accelerate drug discovery in ways traditional pharma computational biology cannot. Coefficient Bio's expertise in protein design and biological simulation gives Anthropic a team that knows what to ask the models. [3]

The acquisition landed the same day OpenAI bought TBPN, a media company. Katie Roof at The Information noted the contrast: "Anthropic made a very different kind of acquisition than OpenAI today." [4] One bought viewers. The other bought scientists.

Whether $400 million for 10 people with no product is genius or insanity depends on what Claude can do with biology. That answer is years away. The bet is now.

-- THEO KAPLAN, San Francisco.